FDA fills four senior roles, including top officials for drugs, vaccines and tobacco
Summary
The FDA under President Donald Trump has filled four senior positions with permanent leaders, ending several months of temporary appointments. These roles include top officials for drug approval, vaccines, and tobacco products, areas that have seen major policy changes and attracted attention from lawmakers and consumer groups.Key Facts
- President Donald Trump’s administration named permanent directors for the FDA’s centers focused on drugs, vaccines, and tobacco.
- Dr. Michael Davis was appointed head of the Center for Drug Evaluation and Research, responsible for drug safety and effectiveness.
- Davis has experience in psychiatric drugs and previously worked on developing psychedelic drugs like psilocybin, MDMA, and LSD, which are being studied for mental health use.
- Karim Mikhail was named director of the FDA’s vaccine center; he replaced Dr. Vinay Prasad, who resigned amid controversies about vaccine policies and gene therapies.
- Prasad had criticized the FDA’s approach to COVID-19 vaccines and worked on stricter rules for approving updated vaccines.
- The FDA has cleared new tobacco-related products like nicotine pouches and e-cigarettes after the resignation of former Commissioner Marty Makary.
- These appointments aim to bring stability to the FDA after months of leadership changes and policy debates.
- The changes come during ongoing government efforts to speed up review times for psychedelic drugs and regulate tobacco and vaccine products.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
